Skip to content

Study · Animal study (in vivo) · dog · 2011

4 results

Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade.

Hermo GA, Turic E, Angelico D, Scursoni AM, Gomez DE, Gobello C, Alonso DF

Journal of the American Animal Hospital Association16 Dec 2010Cited by 23 (Europe PMC)

PMID21164169 (opens in a new tab)DOI10.5326/jaaha-ms-5509 (opens in a new tab)PepBankPUB-21164169
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with grade 2 or 3 mammary carcinoma, desmopressin significantly prolonged disease-free survival versus control (P<0.001).

    In plain wordsIn dogs with grade 2 or 3 mammary cancer, desmopressin prolonged cancer-free survival compared with placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseDisease-free survival in grade 2 or 3 carcinoma
    Study

    dogn: not reported in source

    Intact bitches with stage III or IV mammary carcinoma undergoing mastectomy
    Comparator
    Saline placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 μg/kg · intravenousAs given in this study (dog).

    Source sentences

    Summary
    DDAVP therapy significantly prolonged the disease-free survival (P<0.001) and overall survival (P<0.01) in bitches with grade 2 or 3 carcinomas compared with bitches in the control group.
    3 context sentences
    Summary · context
    Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included.
    Summary · context
    These dogs were randomized to receive DDAVP at intravenous doses of 1 μg/kg (n=18) or saline solution as placebo (n=10).
    Summary · context
    En bloc mastectomy of the affected gland(s) was performed.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with grade 2 or 3 mammary carcinoma, desmopressin significantly prolonged overall survival versus control (P<0.01).

    In plain wordsIn dogs with grade 2 or 3 mammary cancer, desmopressin prolonged survival compared with placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseOverall survival in grade 2 or 3 carcinoma
    Study

    dogn: not reported in source

    Intact bitches with stage III or IV mammary carcinoma undergoing mastectomy
    Comparator
    Saline placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    1 μg/kg · intravenousAs given in this study (dog).

    Source sentences

    Summary
    DDAVP therapy significantly prolonged the disease-free survival (P<0.001) and overall survival (P<0.01) in bitches with grade 2 or 3 carcinomas compared with bitches in the control group.
    3 context sentences
    Summary · context
    Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included.
    Summary · context
    These dogs were randomized to receive DDAVP at intravenous doses of 1 μg/kg (n=18) or saline solution as placebo (n=10).
    Summary · context
    En bloc mastectomy of the affected gland(s) was performed.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with grade 1 mammary tumors, disease-free period did not significantly differ between desmopressin and control.

    In plain wordsIn dogs with grade 1 mammary tumors, cancer-free time did not significantly differ between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeDisease-free period in grade 1 tumors
    Study

    dogn: not reported in source

    Intact bitches with stage III or IV mammary carcinoma undergoing mastectomy
    Comparator
    Saline placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 μg/kg · intravenousAs given in this study (dog).

    Source sentences

    Summary
    No significant difference in disease-free period or overall survival was found between treatment groups in bitches with grade 1 tumors.
    3 context sentences
    Summary · context
    Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included.
    Summary · context
    These dogs were randomized to receive DDAVP at intravenous doses of 1 μg/kg (n=18) or saline solution as placebo (n=10).
    Summary · context
    En bloc mastectomy of the affected gland(s) was performed.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In dogs with grade 1 mammary tumors, overall survival did not significantly differ between desmopressin and control.

    In plain wordsIn dogs with grade 1 mammary tumors, survival did not significantly differ between desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeOverall survival in grade 1 tumors
    Study

    dogn: not reported in source

    Intact bitches with stage III or IV mammary carcinoma undergoing mastectomy
    Comparator
    Saline placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    1 μg/kg · intravenousAs given in this study (dog).

    Source sentences

    Summary
    No significant difference in disease-free period or overall survival was found between treatment groups in bitches with grade 1 tumors.
    3 context sentences
    Summary · context
    Of the 32 dogs initially recruited, 28 intact bitches with mammary carcinoma tumors stage III or IV were ultimately included.
    Summary · context
    These dogs were randomized to receive DDAVP at intravenous doses of 1 μg/kg (n=18) or saline solution as placebo (n=10).
    Summary · context
    En bloc mastectomy of the affected gland(s) was performed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.